Ramucirumab

Red

Brand Name(s):Cyramza

Indication:Cancer – gastric, gastro-oesophageal, metastatic colorectal cancer & small cell lung cancer
Metastatic non-small cell lung cancer with activating growth factor mutations in combination with Erlotinib

Rationale:1,2,3

Considered:Feb-15

Review Date:Feb-25

Comments:
SPC has been updated to include information of new licenseing in combination with Erlotinib for first-line treatment of adults with metastatic non-small cell lung cancer with activating epidermal growth factor receptor mutations https://www.medicines.org.uk/emc/product/3640/smpc

NICE TA403 Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Aug 2016
NICE TA378
Ramucirumab for treating advanced gastric cancer or gastro oesophageal junction adenocarcinoma previously treated with chemotherapy. Document available at:http://www.nice.org.uk/guidance/ta378
Jan-16